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Editorial on the Research Topic
Complement and Immunotherapeutics
The complement system was discovered more than 100 years ago as an ancient defense system
that prevents pathogens’ invasion. For a long time, the complement was considered a scientifically
interesting system with limited physiological relevance. However, it regained interest in the last
decades when thousands of publications on its new role in health and disease appeared. The loss of
proper control on complement activity became an acknowledged etiological factor in numerous
autoimmune/inflammatory diseases. The discovery of complement receptors revealed that this
system is not only an implement to kill microbes but an essential modulator of the immune
responses, metabolism, angiogenesis, tissue repair and development, and many other processes
influencing the overall body homeostasis (1–3). Additional interest in complement as an effector
mechanism of therapeutic antibodies appeared when rituximab, the first antitumor antibody, was
introduced into the clinics in 1997 (4) and a decade later when the first complement-specific drug,
eculizumab was approved (5). Engagement of more than 40 proteins either as structural elements
of the complement cascade or its regulators as well as crosstalk with other pathways creates a
sophisticated network of interactions that keep a delicate balance between the deleterious and
protective nature of the complement. Therefore, it is not surprising that on one hand markers
of complement activation emerge as diagnostic and prognostic tools (6), and on the other hand
increasing number of complement targets for potential therapeutic intervention appears, which are
currently being exploited by registered drugs or compounds that are under evaluation in clinical
trials (7).
This Research Topic entitled “Complement and Immunotherapeutics” presents a collection of
articles describing a broad range of developments in the field of complement-targeting drugs.
The article by Urwyler et al. presents the results of an uncontrolled series of cases, where
patients suffering from SARS-CoV-2 infection were treated with conestat alpha—the recombinant
C1 inhibitor. Out of five patients with severe COVID-19 pneumonia enrolled into the therapeutic
scheme, four patients achieved immediate recovery, and one needed mechanical ventilation,
however, all patients finally recovered. Conestat showed good tolerability. Despite certain
limitations of this study, the results encourage to perform of a controlled clinical trial.
The article by Zelek and Morgan introduces a novel monoclonal antibody targeting C7 and
C5b-7 complex. Such antibody was successfully tested in both in vitro systems and in vivo models
of C7-deficient mouse reconstituted with human C7 or rat model. Such an innovative therapeutic
approach allows targeting of a membrane attack complex formation, a very late step of the cascade,
leaving all upstream steps intact to protect the host from pathogens and clean up cell debris.
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A novel therapeutically useful concept was presented by
Banda et al. and involves natural IgM antibodies (NAbs).
These antibodies are known to recognize injury-associated
epitopes and may contribute to autoimmunity. However, when
engineered, they may be employed to deliver complement
regulators to the site of injury. In this study fusion protein
consisting of NAb-derived fragment and mouse complement
inhibitor Crry was shown to decrease clinical disease activity
in a mouse model of arthritis. Another fusion construct of
factor H (FH) CCP domains 18–20 with Fc fragment of
human IgG1 applicable in combating Neisseria gonorrhoeae
infection was described by. Shaughnessy et al. Point mutation
introduced in CCP19 disabled lysis of human erythrocytes but
left bactericidal potential. Production of recombinant protein in
a high-yield plant system was described and the efficacy of the
product was proven in a mouse model. Staying in the field of
complement inhibitors, de Boer et al. have reviewed the role of
complement regulation in oncological, anemic, renal, eye, and
neurologic pathologies. The authors also discussed the potential
of either full-length or engineered inhibitors and antibodies
targeting complement regulatory proteins in the context of the
abovementioned diseases and unmet clinical needs. Not only
disruption of complement regulation but also deficiency of
essential complement components may lead to autoimmunity.
An example is C1q deficiency, which plays an important role
in the development of systemic lupus erythematosus (SLE). The
comprehensive review by Hosszu et al. discusses the impact of
the C1q/C1qR axis in monocyte-to-dendritic cell differentiation
and how the distortion of this axis leads to disease. Moreover, the
authors deliberate on possible therapeutic strategies to attenuate
pro-inflammatory response in SLE patients.
Two articles in the collection are dedicated to anti-CD20
antibodies. Bondza et al. dissected the mechanistic details
of the interaction between clinically approved anti-CD20
mAbs (rituximab, ofatumumab, and obinutuzumab) and their
target. The authors analyzed the kinetics of interactions and
discussed them in the context of complement activation
and complement-dependent cytotoxicity. Felberg et al.
analyzed the cytotoxic potential of sera as well as the levels
of complement activation markers and retention of rituximab
in patients treated for lymphoproliferative disorders. The
publication concludes that monitoring of the complement
system status and measurement of cell-free rituximab during
therapy may be valuable for clinicians and become the
step forward to personalized treatment for the patient. The
additional potentially relevant parameter in the course of
immunotherapy is chronic, low-level complement activation.
Naseraldeen et al. described complement-activating IgG
hexamers in sera from chronic lymphocytic leukemia (CLL)
patients and the pivotal role of alpha-2 microglobulin in
their formation.
A lot of attention is given to the alternative complement
pathway (AP) in the context of kidney diseases, as uncontrolled
propagation of AP often leads to severe damage and eventually
loss of kidney function. Eculizumab was the first complement
medication approved for the treatment of atypical hemolytic
uremic syndrome (aHUS). The two case-reports illustrate the
heterogeneity of this disease and challenge for clinicians
to establish a correct diagnosis and treatment scheme
and the necessity of monitoring disease progression and
complement status. Lumbreras et al. describe a patient with
a very mild manifestation of aHUS. The aHUS diagnosis
was established when low C3 levels and C3 genetic variant
was detected. The mild phenotype may be explained by
the absence of MCP risk polymorphisms in this patient.
While in good health during publication, the patient should
be closely monitored for signs of aHUS relapse to initiate
complement therapy on time. Bouwmeester et al. described
a case of a severely affected patient with aHUS that under
eculizumab treatment has shown high intra-patient variability
in the serum drug levels and CH50, and decline of renal
function. This case underscores the need for continuous
monitoring of patients under treatment for drug levels and
complement status.
Lammerts et al. studied the nature of properdin binding
to proximal tubular endothelial cells and found that this
process and subsequent AP activation can be blocked by the
recombinant tick protein Salp20. Intravascular hemolysis and
release of heme may lead to acute kidney injury. Merle et
al. assessed the role of the main fluid-phase inhibitor of AP,
FH, in kidney protection from hemolysis-mediated damage.
Authors postulate that FH-based approaches can be exploited as
promising therapeutic strategies. The work by Koopman et al.
focuses on C5b-9 deposition in the kidney. Nowadays, therapies
of renal diseases include blockers of the terminal complement
pathway (e.g., eculizumab), but it is not entirely clear how
C5b-9 contributes to pathological processes since such staining
is not routinely performed. Comparison between healthy and
diseased kidneys, correlation with other histological lesions and
clinical data, and potential prognostic value of C5b-9 deposits
are discussed.
Chronic inflammation is observed in women suffering
from endometriosis. Such inflammatory status may stem
from pathological complement activation fueled by aberrant
regulation of the cascade. Agostinis et al. discussed the prospect
of complement inhibition as a novel therapeutic approach
in endometriosis.
La-Beck et al. reviewed the link between adverse effects of
nanoparticle-based drugs and activation of the complement
system. Complement activation on nanoparticles generates
either opsonins and their cleavage products or release of
anaphylatoxins. Both processes can diminish the efficacy
of nano-encapsulated anticancer therapeutics by uptake
of nanoparticles by immune cells and creation of pro-
tumor microenvironment via C5aR-dependent signaling.
Understanding a complex network of nanoparticles,
complement, and drug pharmacology will aid the improvement
of cancer nanomedicines.
In summary, the current Research Topic is a collection
of 16 original and review articles, which describe novel
candidates for complement-related drugs, mechanistic
insights of drug-target interaction, target cell sensitivity,
nanoparticles-based complement medications, diagnostics,
complement genetic screening, as well as complement
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involvement in the course and treatment of diseases such
as systemic lupus erythematosus (SLE), endometriosis, and
a wide spectrum of kidney diseases. The articles highlight
novelty and future perspectives of recent developments in
these fields.
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